Between January 2000 and April 2019, 104 patients received frontline treatment for CML-MBP at our institution and met our inclusion criteria. Twenty patients were treated with IC + TKI, 20 with HMA + TKI, 56 with TKI alone, and 8 with IC alone. Baseline patient characteristics of ...
(IS) compared with baseline, corresponding with a 3-log reduction Complete molecular response (CMR); nilotinib demonstrated superiority in CMR4 and CMR4.5 (corresponding, respectively, to 4-log [≤ 0.01%] and 4.5-log [≤ 0.0032%] reduction in BCR-ABL/ABL levels according to the IS) Overall...